Browsing ICR Divisions by author "Marsden,"
Now showing items 61-80 of 112
-
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson, D; Cunningham, D; Nankivell, M; Blazeby, JM; Griffin, SM; et al. (2017-09)Background Neoadjuvant chemotherapy before surgery improves survival compared with surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant ... -
Opportunities for research in molecular radiotherapy.
Flux, GD; O'Sullivan, J; Gaze, MN; Prise, KM (2017-03)Cancer has been treated with radiopharmaceuticals for 80 years. A recent National Cancer Research Institute report from the Clinical and Translational Radiotherapy Research Working Group reviews the current status of ... -
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl, A; Cunningham, D; Counsell, N; Hawkes, EA; Qian, W; et al. (2017-07)Background There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized ... -
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár, A; Jones, RL; Stacchiotti, S; Gelderblom, H; Guida, M; et al. (2017-01)Background Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy ... -
Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs, Z; Messiou, C; Wong, HH; Hatcher, H; Miah, A; et al. (2017-04)Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of ... -
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham, D; Stenning, SP; Smyth, EC; Okines, AF; Allum, WH; et al. (2017-03)Background Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients ... -
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply.
Smyth, EC; Allum, WH; Rowley, S; Langley, RE; Cunningham, D (2017-05) -
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth, E; Zhang, S; Cunningham, D; Wotherspoon, A; Soong, R; et al. (2017-12)Purpose: Germline polymorphisms may affect chemotherapy efficacy and toxicity. We examined the effect of polymorphisms in drug metabolism and DNA repair genes on pathologic response rates, survival, and toxicity for patients ... -
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling, M; Morschhauser, F; Bouabdallah, K; Bron, D; Cunningham, D; et al. (2017-09)Background Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms.Patients and methods This phase II study evaluated the response rate of copanlisib ... -
Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani, F; Morano, F; Cunningham, D; Baratelli, C; Kalaitzaki, E; et al. (2017-04)Background Although treatment of localized anal cancer (AC) is well established, very little evidence is available to inform the management of advanced tumors, and the prognosis of these patients remains poor. We have ... -
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
Yang, JC-H; Ou, S-HI; De Petris, L; Gadgeel, S; Gandhi, L; et al. (2017-10)Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up ... -
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
Du, Y; Carrio, I; De Vincentis, G; Fanti, S; Ilhan, H; et al. (2017-09)Purpose Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option ... -
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young, RJ; Litière, S; Lia, M; Hogendoorn, PCW; Fisher, C; et al. (2017-07)Background The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma ... -
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
Crabb, SJ; Birtle, AJ; Martin, K; Downs, N; Ratcliffe, I; et al. (2017-10)Background Docetaxel and prednisolone chemotherapy (DP) extends survival in metastatic castration resistant prostate cancer (mCRPC). However, emergent clinical resistance is almost inevitable. AKT pathway activation is ... -
Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.
Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; et al. (2017-01)Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase ... -
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.
Zhu, AX; Baron, AD; Malfertheiner, P; Kudo, M; Kawazoe, S; et al. (2017-02)Importance REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity ... -
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri, A; Smith, IE; Hills, M; Jones, RL; Johnston, SR; et al. (2017-07)Aims To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 ... -
Renal cell carcinoma.
Hsieh, JJ; Purdue, MP; Signoretti, S; Swanton, C; Albiges, L; et al. (2017-03-09)Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) ... -
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; et al. (2017-04)